Endocrinology
Specialized therapies in targeted indications
Merck Serono is committed to improving the lives of people with a range of endocrine and metabolic disorders. We do this through our unique offering of specialized therapies in targeted indications along with innovative drug delivery devices designed to maximize their full potential.
Merck Serono was a pioneer in making recombinant human growth hormone available for the treatment of growth hormone deficiency in children and adults. Saizen® is indicated in children and adults for the treatment of growth hormone deficiency, as well as in children born small for gestational age (SGA), with Turner Syndrome or chronic renal failure. Recombinant human growth hormone is also used to treat patients suffering from HIV-associated wasting (Serostim®) and for the treatment of short bowel syndrome in patients receiving specialized nutritional support (Zorbtive®).Merck Serono continues to bring benefits to patients through these treatments and its family of easy-to-use drug delivery devices.
In addition to an extensive research and development commitment in Oncology, Neurodegenerative and Autoimmunine and Inflammatory Diseases, Merck Serono pursues focused development in Endocrinology.
More about:
| Disclaimer |
This section gives an overview of our Company's activities in endocrinology. The information may refer to pharmaceutical products, therapeutics or indications not yet registered or approved in a given country. US Residents should consult the EMD Serono, Inc. for information on products approved for sale in the United States of America. |
